EP1121376A1 - Pregnane glucuronides - Google Patents

Pregnane glucuronides

Info

Publication number
EP1121376A1
EP1121376A1 EP99953101A EP99953101A EP1121376A1 EP 1121376 A1 EP1121376 A1 EP 1121376A1 EP 99953101 A EP99953101 A EP 99953101A EP 99953101 A EP99953101 A EP 99953101A EP 1121376 A1 EP1121376 A1 EP 1121376A1
Authority
EP
European Patent Office
Prior art keywords
glucuronide
pregnane
pharmaceutically acceptable
acceptable salt
triol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99953101A
Other languages
German (de)
English (en)
French (fr)
Inventor
Christopher Paul Miller
Bach Dinh Tran
Michael David Collini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1121376A1 publication Critical patent/EP1121376A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16

Definitions

  • estrogenic compositions of substantial purity and low toxicity such as PREMARIN (conjugated equine estrogens) has become a preferred medical treatment for alleviating the symptoms of menopausal syndrome, osteoporosis/osteopenia in estrogen deficient women and in other hormone related disorders.
  • the estrogenic components of the naturally occurring estrogenic compositions have been generally identified as sulfate esters of estrone, equilin, equilenin, 17- ⁇ -estradiol, dihydroequilenin and 17- ⁇ -dihydroequilenin (U.S. Patent 2,834,712).
  • the estrogenic compositions are usually buffered or stabilized with alkali metal salts of organic or inorganic acids at a substantially neutral pH of about 6.5 to 7.5.
  • Urea has also been used as a stabilizer (U.S. 3,608,077).
  • the incorporation of antioxidants to stabilize synthetic conjugated estrogens and the failure of pH control with tris(hydroxymethyl)aminomethane (TRIS) to prevent hydrolysis is discussed in U.S. 4,154,820.
  • Pharmaceutically acceptable salts of 5 ⁇ -Pregnane-3 ⁇ ,(20S), 21-triol 20-O- ⁇ - glucuronide and 5 ⁇ -Pregnane-3 ⁇ ,20R-diol 20-O- ⁇ -glucuronide are not limited to the naturally occurring form, but also include the alkali metal salts, alkaline earth metal salts, ammonium salts, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, and trialkylammonium salts containing 1-6 carbon atoms in each alkyl group as well as any other atom or molecules which have a positive charge.
  • this invention also provides 5 ⁇ -Pregnane-3 ⁇ ,(20S), 21-triol 20-O- ⁇ -glucuronide and 5 ⁇ -Pregnane-3 ⁇ ,20R-diol 20-O- ⁇ -glucuronide and their pharmaceutically acceptable salts in greater than 1 percent purity.
  • This invention also provides compounds consisting essentially of 5 ⁇ -
  • This invention further provides a method of using 5 ⁇ -Pregnane-3 ⁇ ,(20S), 21- triol glucuronide and 5 ⁇ -Pregnane-3 ⁇ ,20R-diol glucuronide or a pharmaceutically acceptable salt of the related glucuronides as progestational agents.
  • the starting materials used in this synthesis are either commercially available or can be prepared using standard chemical methodology.
  • the compounds of this invention are progestational agents, and are therefore useful as oral contraceptives (male and female), in hormone replacement therapy (particularly when combined with an estrogen), in the treatment of endometriosis, luteal phase defects, benign breast and prostatic diseases and prostatic and endometrial cancers.
  • the compounds of this invention are also useful in protecting against epileptic seizures, in cognition enhancement, in treating Alzheimer's disease, dementias, vasomotor symptoms related to menopause, and other central nervous system disorders
  • the compounds of this invention are further useful in stimulating erythropoieses.
  • the compounds of this invention can be used alone as a sole therapeutic agent or can be used in combination with other agents, such as other estrogens, progestins, or androgens.
  • the compounds of this invention can be formulated neat or with a pharmaceutical carrier for administration, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmacological practice.
  • the pharmaceutical carrier may be solid or liquid.
  • a solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents: it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
  • the active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g.
  • cellulose derivatives preferably sodium carboxymethyl cellulose solution
  • alcohols including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, lethicins, and oils (e.g. fractionated coconut oil and arachis oil).
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
  • the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
  • the compounds of this invention can also be administered orally either in liquid or solid composition form.
  • the compounds of this invention may be administered rectally or vaginally in the form of a conventional suppository.
  • the compounds of this invention may be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol.
  • the compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin.
  • the carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
  • the creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type.
  • Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable.
  • a variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.
  • the dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular subject being treated.
  • the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example, packaged powders, vials, ampoules, pre filled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • Example 5 5 ⁇ -Pregnane-3 ⁇ .20S.21-triol 20-O- ⁇ -D- lucuronide sodium salt 8
  • Compound 7 (1.57 g, 1.7 mmol) was suspended in MeOH (20 mL) and treated with an aqueous solution of NaOH (6.4 mL, 0.5 N) and stirred for 5 minutes which allowed all of the starting material to go into solution. The solution was then mixed with 0.65 g of product from a previous run and the combination stripped onto silica gel and column chromatographed on silica gel (MeOH:CH 2 Cl 2 , 4:6 then 5:5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99953101A 1998-10-13 1999-10-07 Pregnane glucuronides Withdrawn EP1121376A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17034298A 1998-10-13 1998-10-13
US170342 1998-10-13
PCT/US1999/023467 WO2000021977A1 (en) 1998-10-13 1999-10-07 Pregnane glucuronides

Publications (1)

Publication Number Publication Date
EP1121376A1 true EP1121376A1 (en) 2001-08-08

Family

ID=22619512

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99953101A Withdrawn EP1121376A1 (en) 1998-10-13 1999-10-07 Pregnane glucuronides

Country Status (17)

Country Link
EP (1) EP1121376A1 (ko)
JP (1) JP2002527448A (ko)
KR (1) KR20010080102A (ko)
CN (1) CN1330659A (ko)
AR (1) AR020778A1 (ko)
AU (1) AU751708B2 (ko)
BR (1) BR9914521A (ko)
CA (1) CA2346693A1 (ko)
CZ (1) CZ20011343A3 (ko)
EA (1) EA200100437A1 (ko)
HU (1) HUP0103992A3 (ko)
IL (1) IL142441A0 (ko)
NO (1) NO20011825L (ko)
PL (1) PL347270A1 (ko)
TW (1) TW499435B (ko)
WO (1) WO2000021977A1 (ko)
ZA (1) ZA200103012B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
KR100440607B1 (ko) * 2001-12-28 2004-07-15 주식회사 엘컴사이언스 프레그난 배당체 화합물 및 이를 유효성분으로 함유하는퇴행성 뇌신경계 질환의 예방 및 치료제

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029011B (en) * 1978-09-01 1983-02-02 Coulson W Use of a synthetic bifunctional ligand for the immunimetric determination of the concentration ratio of two solutes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0021977A1 *

Also Published As

Publication number Publication date
HUP0103992A2 (hu) 2002-04-29
BR9914521A (pt) 2001-06-26
AU6511599A (en) 2000-05-01
TW499435B (en) 2002-08-21
AU751708B2 (en) 2002-08-22
NO20011825L (no) 2001-06-05
WO2000021977A1 (en) 2000-04-20
JP2002527448A (ja) 2002-08-27
EA200100437A1 (ru) 2001-10-22
CN1330659A (zh) 2002-01-09
CZ20011343A3 (cs) 2002-04-17
NO20011825D0 (no) 2001-04-10
AR020778A1 (es) 2002-05-29
ZA200103012B (en) 2002-07-11
PL347270A1 (en) 2002-03-25
KR20010080102A (ko) 2001-08-22
HUP0103992A3 (en) 2002-12-28
IL142441A0 (en) 2002-03-10
CA2346693A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
AU751708B2 (en) Pregnane glucuronides
AU739146B2 (en) Pregnan-3-ol-20-ones
US20010007859A1 (en) Pregnane glucuronides
US6713465B1 (en) Pregnanes
AU746326B2 (en) Pharmaceutically acceptable salts of 5alpha-pregnan-3beta, 16alp ha-diol-20-one 3-sulfate useful as progestins and CNS disorders
US6458778B1 (en) Estradienes
MXPA01003699A (es) Glucuronidos de pregnano
AU738486B2 (en) Estra-5(10),7-dienes with estrogenic activity
EP0980381B1 (en) Pharmaceutically acceptable salts of 5.alpha.-pregn-16-en-3.beta.-ol-20-one 3-sulphate ester with progestin activity and useful in the treatment of cns disorders
EP0338065B1 (fr) Derives de la 19-nor progesterone, leur preparation et leur utilisation
EP0980382B1 (en) Estrogenic 19-norandrost-17-one derivatives with an aromatic b-ring
EP0980384A1 (en) Pregnane 3,2o diol mono- and di-sulphates
AU730300B2 (en) Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens
AU750306B2 (en) B-ring estratriene diol sulphates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010330;LT PAYMENT 20010330;LV PAYMENT 20010330;MK;RO PAYMENT 20010330;SI PAYMENT 20010330

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040504

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036992

Country of ref document: HK